[What shall we make of the arrival of "generalized" antibiotics to anti-Hansen's therapy?].
J M
JM
Decazes
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D017291:Clarithromycin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000075202:Contraindications; D003906:Developing Countries; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007917:Leprostatic Agents / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy*; D023421:Models, Animal; D009166:Mycobacterium leprae / Q000187:drug effects; D015242:Ofloxacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012449:Safety
D000900:Anti-Bacterial Agents; D007917:Leprostatic Agents; D015242:Ofloxacin; D017291:Clarithromycin